Biostimulant Patents: Who Leads, Where the Gaps Are 2026
- Concentrated but not locked. the ranked leader holds 33 records, yet the top 5 assignees combined account for only 25.5% of all 365 records in scope — most of the field sits with a long tail of single- and few-filing entrants.
- Filing kept climbing through the last complete year. filings rose 47% from 43 in 2021 to 63 in 2024, the peak year on record, before the expected publication-lag dip in 2025-2026.
- Claims cluster on formulation, not mechanism. A01N biocide/agrochemical composition classes cover 64.4% of records versus 15.3% for C12N microorganism and genetic-engineering claims — the microbial mode-of-action space is comparatively open.
Filing growth compares 2021 (43 records) with 2024 (63) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 365 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 365 published patent records filed between 2015 and mid-2026 that combine biostimulant subject matter — seaweed extracts, microbial inoculants, and related formulations — with claim language on mode of action, yield-response consistency, formulation shelf life, compatibility, regulatory classification or claim substantiation. Those last terms matter: they push the corpus toward filings that try to prove or standardise a stress-tolerance effect, not just describe a fertiliser blend.
Filing activity is distributed across agrochemical formulation, organic fertiliser, and microbial engineering classes, with receiving offices spanning WIPO, the US, India, Europe, Canada and China. The mix suggests a technology still being defined at the formulation and evidentiary level rather than one settled around a single dominant mechanism.
Filing trend and technology composition
Two views of the same 365-record corpus: filings by year, and the IPC subclasses those filings claim under. Because a single record can carry several IPC codes, the class shares below sum to more than 100% of records.
Filing trend, 2017-2026
Filings grew from 18 in 2017 to a peak of 63 in 2024, including a 47% rise from 43 (2021) to 63 (2024). 2025 and 2026 show fewer published records, but that reflects the roughly 18-month gap between filing and publication, not a real slowdown — 2024 is the last year that can be read as complete.
IPC subclass composition
A01N agrochemical/biocide claims dominate at 64.4% of the 365 records, followed by A01P pesticide-activity claims at 36.7% and C05F organic fertiliser claims at 32.6%. C12N microorganism and genetic-engineering claims sit lower at 15.3%, and C12M bioreactor/enzyme apparatus claims at 6.8% — both comparatively thin given how central microbial biostimulants are to the topic.
Shares are the percentage of the 365 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biostimulants for Crop Stress Tolerance with Eureka
This page is one run against one query. Ask Eureka your own question about biostimulants for crop stress tolerance and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this corpus
WO2026146424A1 — Biodegradable and biostimulant pot and uses thereof
A biodegradable plant pot combining structural support with biostimulant function: made of renewable natural materials and a biodegradable binder, with microalgae incorporated directly into the pot material. The porous structure balances water retention and aeration while the microalgae and any additives release gradually as the pot biodegrades in soil or substrate, aimed at reducing irrigation needs and improving climate resilience during early plant growth.Filed by OPRIMEE – Innovation Design Engineering Solutions, Lda, published 2026-07-09 — one of the most recent records in scope.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20220272987A1 | Composition including effervescent agents, biostimulant, nutrient, and pesticide | 43 |
| 2 | WO2023154183A1 | Composition including effervescent agents, biostimulant, nutrient, and pesticide | 33 |
| 3 | US20230172194A1 | Composition including effervescent agents, biostimulant, nutrient, and pesticide | 25 |
| 4 | US20070051676A1 | Agent and method for decontaminating soil, groundwater or sediment contaminated with hexavalent chromium | 18 |
| 5 | US20200214286A1 | Novel biostimulants for enhancing crop productivity, methods and uses thereof | 15 |
| 6 | WO2019155252A1 | Novel bacillus SP. simplex and uses thereof | 15 |
| 7 | WO2019155253A1 | Novel paenibacillus polymyxa and uses thereof | 14 |
| 8 | CN113999071A | 促生抗逆提质氨基酸水溶肥及其制备方法和用途 | 13 |
| 9 | WO2011067752A1 | Device used for treatment of rhinitis by biostimulative illumination | 11 |
| 10 | WO2022024050A1 | Microbial strains bacillus pumilus, bacillus megaterium and uses thereof | 10 |
Citation counts are pulled from within this searched corpus and skew toward older filings that have had more time to accumulate citations — read them as a signal of influence, not of current technical importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Three read-throughs from the concentration, growth and classification data above.
A leader, not a lock
The top-ranked assignee holds 33 records and the top 5 combined reach 25.5% of the 365 records in scope. That leaves roughly three-quarters of the corpus spread across a long tail of the remaining 95 ranked companies, many with only one or two filings.
Sustained build, not a spike
Filings climbed from 43 in 2021 to 63 in 2024, the corpus peak. Because publication trails filing by about 18 months, the lower counts shown for 2025-2026 are an artefact of the pipeline, not evidence the field has cooled.
Formulation is crowded, mechanism less so
A01N agrochemical composition claims cover 64.4% of records, but C12N microbial and genetic-engineering claims sit at just 15.3%, and C12M bioreactor/enzyme apparatus claims at 6.8%. For a category built partly on microbial inoculants, the underlying biological mechanism claims are thinner than the formulation layer around them.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biostimulants for crop stress tolerance, with the prior art for and against each one.
Who is filing, and where momentum sits
The ranking covers 100 companies as returned by the data endpoint — not a curated top-50 or top-100 list. Filing counts and recent-year momentum both point to a field where the leader keeps filing while several once-active names have gone quiet.
Single largest filer
The top-ranked assignee holds 33 records, well ahead of the fifth-place company at 13 and the tenth-place company at 8 — a real gap at the very top even though the combined top-5 share of all records stays modest.
Cooling among earlier filers
Several assignees that built meaningful portfolios earlier in the window show zero filings in the latest year, some down 100% year-on-year, while at least one established seaweed-extract filer still logged filings in the same period.
Co-filing is rare, and concentrated
Only five co-assignee pairs appear in the corpus, and the strongest single pairing recurs four times between the same two organisations. Joint filing is not yet a common strategy in this space.
| Assignee | Recent year | YoY |
|---|---|---|
| Acadian Seaplants Ltd | 3 | — |
| Tenfold Technologies LLC (doing business as AgriCen Sciences) | 0 | -100% |
| STRING BIO | 0 | — |
| UPL Corporation Ltd | 0 | — |
| Enlightened Soil Corp | 0 | -100% |
| Lipofabrik | 0 | -100% |
| Oro Agri Europe SA | 0 | — |
| EnviroKure Inc | 0 | — |
Where to take this
The dataset points to specific next steps depending on whether you are filing, licensing, or clearing a product for launch.
Check freedom to operate on formulation claims
A01N and C05F classes carry the densest claim coverage in this corpus. Any new biostimulant formulation should be checked against this density before drafting, particularly where effervescent or multi-agent delivery is involved.
Run a freedom-to-operate search in Eureka →Explore the microbial mechanism white space
C12N and C12M claim shares are thin relative to how central microbial inoculants are to the category. A first claim tied to a specific, substantiated mode of action could sit in genuinely open space.
Explore this branch in Eureka →Track leader filing behaviour over time
The top assignee continues to file while several earlier-active companies show no recent output. Watching who re-enters the field is as informative as watching who leads it.
Set up assignee tracking in Eureka →Common questions
This landscape covers 365 published patent records filed between 2015 and mid-2026 that combine biostimulant subject matter with claim language on mode of action, yield-response consistency, formulation shelf life, compatibility, regulatory classification or claim substantiation. That scoping means the corpus skews toward filings trying to demonstrate or standardise an effect, rather than every biostimulant patent in existence. Filing activity peaked in 2024 at 63 records, with 2025-2026 figures still filling in due to normal publication lag.
Filings are led by one assignee holding 33 records, well ahead of the fifth-place company at 13 and the tenth at 8. Despite that gap at the top, the five largest filers together account for only 25.5% of all 365 records in scope, meaning most of the field is held by a long tail of smaller filers rather than a handful of dominant players. Recent-year momentum data also shows several earlier-active filers with zero filings in the latest year, so leadership by cumulative count does not always match current activity.
Yes, through the last year that can be read reliably. Filings rose 47% from 43 in 2021 to a peak of 63 in 2024. Counts for 2025 and 2026 appear lower, but that reflects the roughly 18-month lag between filing and publication rather than a genuine slowdown, so 2024 should be treated as the most recent complete data point.
The corpus is dense in agrochemical formulation claims: A01N biocide/agrochemical composition classes cover 64.4% of the 365 records and A01P pesticide-activity claims cover 36.7%. By contrast, C12N microorganism and genetic-engineering claims sit at only 15.3% and C12M bioreactor/enzyme apparatus claims at 6.8%, despite microbial inoculants being central to the category. That gap suggests the underlying biological mechanism and production-process layers are comparatively open compared with the crowded formulation layer around them.
Rarely. Only five co-assignee pairs appear across the 365 records in this corpus, and the strongest recurring pairing appears just four times between the same two organisations. Most filings in this field are made by a single assignee rather than through joint ventures or co-development agreements, which is worth noting when assessing partnership or licensing risk around a given portfolio.
Research Biostimulants for Crop Stress Tolerance in depth with Eureka
Go past this page: query the whole biostimulants for crop stress tolerance corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.